Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients.

Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers.

An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients.

A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression.

A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response.

Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types.

Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir*

Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research.

Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools.

A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection.

Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring.

Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer.

The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival.

Liquid biopsy may replace invasive procedure to detect cancer: Experts

In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification.

The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process…

Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume...

"OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs.

Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood.

Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection.